1st-line benefit in combination with widely approved CDK4/6 inhibitors Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful无进展生存期(PFS)的主要终点的改善。该试验评估了切换到芳香酶抑制剂(AI)(ANASTROZOLE或LETROOZOLE)与CDK4/6抑制剂在一线治疗激素受体(HR)患者(HR)蛋白(HR) - 蛋白蛋白酶(Her2)型乳腺较大较大的癌症中的一线治疗中,与CDK4/6抑制剂结合使用了CDK4/6抑制剂,将切换到持续的护理标准治疗。